Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Effector Therapeutics Inc (NQ: EFTR ) 0.1800 UNCHANGED Last Price Updated: 4:00 PM EDT, Jul 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Effector Therapeutics Inc < Previous 1 2 Next > eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq June 24, 2024 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer May 20, 2024 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update May 09, 2024 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics to Participate in Upcoming Investor Conference April 09, 2024 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer April 04, 2024 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update March 25, 2024 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference February 05, 2024 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules January 29, 2024 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules January 25, 2024 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024 January 09, 2024 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics Announces Reverse Stock Split January 09, 2024 EFTR common stock expected to begin trading on a split-adjusted basis on January 12, 2024 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients December 08, 2023 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer November 28, 2023 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR to Present New Clinical Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Patients with ER+ Metastatic Breast Cancer at SABCS 2023 Annual Meeting November 15, 2023 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update November 13, 2023 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare Conference November 06, 2023 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid Leukemia October 24, 2023 Trial designed to capitalize on previously published results that showed preclinical activity of tomivosertib in AML models From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors September 11, 2023 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences August 30, 2023 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update August 08, 2023 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics Raises a Total of $16.2 Million in Gross Proceeds from Two Recent Registered Direct Offerings June 08, 2023 eFFECTOR Closes Second Registered Direct Offering Priced At-The-Market Under Nasdaq Rules From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics Announces $8.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules June 07, 2023 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics Announces Closing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules May 31, 2023 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules May 26, 2023 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics Reports Positive Data Updates from Phase 2 Expansion Cohorts Evaluating Zotatifin in Patients with ER+ Metastatic Breast Cancer at the ASCO 2023 Annual Meeting May 25, 2023 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update May 09, 2023 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics to Present at JMP Securities Life Sciences Conference May 08, 2023 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR to Present Updated Clinical Data from Phase 2 Expansion Cohorts for Zotatifin in Patients with ER+ Metastatic Breast Cancer at ASCO 2023 Annual Meeting April 26, 2023 eFFECTOR to host conference call following ASCO presentation From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics to Collaborate with Stanford Medicine on Investigator-Initiated Randomized Phase 2 Study in Patients with ER+ Breast Cancer April 11, 2023 The Company’s eIF4A inhibitor, zotatifin, will be tested in specific genomically-defined subgroups, including standard risk patients as well as high-risk patients carrying specific markers predictive... From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences March 28, 2023 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.